Skip to contentG
Gossamer Bio, Inc.
G
GOSSGossamer Bio, Inc. Q1 2025 · 10-Q
Revenue$9.89M$9.89M— vs Q1 2024 Net Income-$36.64M-$36.64MN/M vs Q1 2024 EPS Diluted-$0.16-$0.16N/M vs Q1 2024 Operating Income-$36,810,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Gossamer Bio, Inc. · CIK 1728117 · Engraved from SEC EDGAR
Free Cash Flowderived-$39,750,000N/M Margins · derivedOperating margin-372.2%
Net margin-370.5%
ended Mar 31, 2025 · filed May 15, 2025 · 45 d after period end